Short Interest Drops
Better late than never, eh?
NYSE short interest for the period between mid-August and mid-July dropped 0.27%. NASDAQ short interest also declined (-0.16%). Boo's crew mostly took a break this month.
The graph I've been using appears below. It uses January 2003 as an index year (for no reason than that was a complete year bull market and the first year where I collected data. I'm not certain the graph is anything more than informational, but I think it is worth pointing out the pattern of the indexed NADSAQ Comp (in dark blue) after each time it was eclipsed by the indexed value of the NASDAQ short interest (light blue).
For the first time since May and for only the third time this year, 155 stocks in the NASDAQ Biotech Index (NBI) dropped (-2.36%). Two companies dropped off this list during this period, but the average short interest also dropped during the month. Short interest of the NBI as a percentage of overall NASDAQ short interest is now at 11.56%, down slightly from last month's 11.84% for the second drop in this measure in as many months. The decrease in biotech short interest came in the face of an overall up move in the NBI of 3.41%, the third straight month-over-month gain..
Beginning in May, I started tracking short interest in biotechnology stocks that ended up on the Regulation SHO Category A and B lists (read more about this here). These stocks were selected because they were members of the NASDAQ Biotech Index (NBI) at the time the SHO Part Two rule was initiated. Short interest in these stocks decreased in the last measurement period by -1.65%. However, the average short interest increased by 0.11%. This discrepancy is likely caused by the removal of Vicuron during the measurement period. If one looks at the average short interest measurement, it has increased in this subpopulation every month since Reg. SHO went into effect despite two down months in the overall biotech sector in the same period.
Short interest in the IBB, the iShare ETF for the NASDAQ Biotech Index (NBI), declined 1.39% to 8.49M shares last month. This is the third straight monthly drop. The BBH, a HOLDr ETF approximating the AMEX Biotech Index, saw short interest increase 7.63% to 3M shares, breaking a string of five straight monthly drops.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Daily Recap Newsletter